Giles takes the helm of PPTA at a time of heightened awareness of plasma donation, with significant opportunity to broaden understanding of the plasma protein therapeutics sector.
Together with other members of the Global Board, Giles will support PPTA’s goals to improve understanding of the need for plasma, highlighting the importance, unique nature and value of plasma therapies to rare disease communities globally.
Advocating strongly for global and reliable sufficiency of plasma, he will also drive progressive policies for plasma donation and guide PPTA as we strive to improve and increase patient access to plasma medicines.
As the EU introduces revisions to EU blood legislation and General Pharmaceutical Legislation, Giles will guide and support PPTA policy priorities to help ensure that the new legislation reflects the needs of industry and that we continue to deliver value to patients and healthcare systems.
Among issues Giles will address in the U.S. are the need to ensure value recognition for plasma therapies across key stakeholders; building bipartisan, bicameral support in Congress for the creation of a Plasma Caucus; and to open up plasma donation for as many people as possible
Giles comes to PPTA with over 20 years of experience in the pharmaceutical sector. Recently appointed as President of Plasma-Derived Therapies at Takeda, he was formerly President of Europe & Canada and chaired the innovation committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
He has been part of the Takeda Executive team for eight years and worked in Europe, Asia, the Middle East and South America. He is currently based in the United States.